The role of the JAK-STAT pathways in the regulation of cytokines, particularly type 1 cytokine receptors: ILs including IL-12 and IL-23 and type 2 cytokine receptors including IFN and IL-10-related cytokines [IL-10, IL-19, IL-20, IL-22, IL-26] could warrant a new therapeutic target for HS patients [67]. The gene discussed is IL26; the disease is histiocytic sarcoma.